Draft. Pending scientific and legal review. Not medical advice.

Pharmacogenomics: genetic variants and drug response

Pharmacogenomics analyses variants in genes linked to absorption, distribution, metabolism and excretion of medicines. It may help guide drug choice or dose according to clinical guidelines. It does not replace medical judgement and must not lead to changing treatment without professional supervision.

What this area studies

Pharmacogenomics examines how a person's genetic variants influence the way the body processes medicines and responds to them. The Xenomium catalogue describes pharmacogenetic profiles focused on polymorphisms in key ADME genes (absorption, distribution, metabolism and excretion).

Gene families often included are phase I and II hepatic enzymes (for example the CYP450 family, UGT, NAT2 or TPMT), transporters (such as SLCO1B1 or ABCB1) and drug targets or receptors. Some pleiotropic genes may modify overall treatment response.

Genotype does not change over a lifetime. A well-indicated study may inform present and future treatments, always interpreted in the person's clinical context.

Study types in the catalogue

This service line lists profiles with different coverage. A narrower profile focuses on genes strongly related to ADME processes; another offers extended coverage on the same pharmacogenomic axis. Both are polymorphism studies, not disease diagnoses.

Specific methods and gene lists appear on the professional catalogue sheets. This page does not replace that technical sheet and does not list prices or turnaround times: those details, when available, are confirmed with the team after a clinical indication.

The sample is usually obtained once (saliva or blood, according to the laboratory protocol). Genotype does not change; clinical usefulness still depends on the medicine, dose and patient context being reassessed with the professional whenever treatment changes.

How results are interpreted (CPIC, DPWG, PharmGKB)

Dose or alternative-drug recommendations draw, where appropriate, on international clinical guidelines. CPIC and DPWG publish drug-genotype guidelines. PharmGKB curates evidence and evidence levels for gene-drug pairs.

A pharmacogenomic report may flag:

- Toxicity risk: medicines that may accumulate or cause adverse effects. - Lack of efficacy: medicines that may not reach the expected effect. - Dose adjustment or a therapeutic alternative, when the guideline contemplates it.

That reading supports prescribing. It does not replace the clinician's judgement or assessment of age, weight, liver and kidney function, interactions or habits. ClinGen may provide context on the clinical validity of certain genes; application to the individual patient remains clinical.

Relation to other catalogue lines

In psychiatry, the genetic question may concern susceptibility (BrainGenomarkers panels) or response to psychotropic medicines (pharmacogenomics). In nutrigenomics, the panel GLP-1 block is pharmacogenetics of a prescription medicine, not a nutrition recommendation.

This page does not recommend molecules or doses. Any therapeutic change requires professional supervision.

Limits and cautions

Treatment must not be changed or stopped without consulting a healthcare professional. Drug response depends on genetic and non-genetic factors.

A genetic result may affect biological relatives and, in some settings, include unsolicited findings. Information, consent and, where required, genetic counselling before testing are not completed on this site.

Pending Phase 0: usual sample type, indicative turnaround, coverage sensitivity and a sample report for this area, once the laboratory supplies them.

Sources

Request through your healthcare professional